Biogen BIIB Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $9.89B+2.2% | $9.68B-1.6% | $9.84B-3.3% | $10.17B-7.4% | ||
| $2.4B+4.1% | $2.31B-8.8% | $2.53B+11.2% | $2.28B+8.0% | ||
| $7.49B+1.6% | $7.37B+0.9% | $7.3B-7.5% | $7.9B-11.0% | ||
| 75.7%-0.4pp | 76.1%+1.9pp | 74.2%-3.4pp | 77.6%-3.2pp | ||
| $1.78B-10.2% | $1.98B-19.0% | $2.45B+9.6% | $2.23B-10.8% | ||
| $2.43B+1.2% | $2.4B-5.7% | $2.55B+6.1% | $2.4B-10.1% | ||
| $8.33B+7.3% | $7.77B-9.0% | $8.54B+29.7% | $6.58B-24.6% | ||
| —— | —— | —— | —— | ||
| -$302.6M+11.9% | -$343.6M-8.9% | -$315.5M-104% | -$154.4M+85.9% | ||
| $1.61B-15.4% | $1.91B+47.0% | $1.3B-63.9% | $3.59B+106% | ||
| $270.7M-1.1% | $273.8M+102% | $135.3M-78.6% | $632.8M+1,108% | ||
| $1.34B-17.8% | $1.63B+40.6% | $1.16B-61.9% | $3.05B+95.8% | ||
| 13.6%-3.3pp | 16.9%+5.1pp | 11.8%-18.1pp | 29.9%+15.8pp | ||
| $9.14-18.3% | $11.19+40.2% | $7.98-61.9% | $20.94+101% | ||
| $2.59B-6.4% | $2.77B+40.8% | $1.97B-56.3% | $4.5B+35.2% | ||
| 26.2%-2.4pp | 28.6%+8.6pp | 20%-24.2pp | 44.2%+13.9pp | ||
| $1.81B-13.5% | $2.1B+42.4% | $1.47B-63.0% | $3.98B+40.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Biogen's revenue?
- Biogen (BIIB) generated $9.9B in revenue over the trailing twelve months, up 1.2% year over year.
- Is Biogen profitable?
- Biogen reported $1.4B in net income over the trailing twelve months, a 14.3% net margin.
- What are Biogen's profit margins?
- Gross margin is 75.5% and operating margin is 22.9%, with a 14.3% net margin.
- What is Biogen's earnings per share?
- Biogen's diluted EPS over the trailing twelve months is $9.65.
- Where does Biogen's income statement data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
